Key result
Cloud-based telehealth linked to a ~120% higher rate of MR regression versus usual care.
Why the study?
Telemedicine is associated with better cardiovascular outcomes, but its effects on the regression of mitral regurgitation and tricuspid regurgitation remain unknown.
Does a cloud-based synchronous telehealth program improve the regression of moderate or greater mitral or tricuspid regurgitation compared to usual care?
Cohort (n=509)
Does a cloud-based synchronous telehealth program improve the regression of moderate or greater mitral or tricuspid regurgitation compared to usual care?
A cloud-based telehealth program was associated with a 2.2-fold higher likelihood of mitral regurgitation regression, which was linked to reverse cardiac remodeling and improved survival.
Answers are grounded in this paper and cite their sources.
Supports telehealth exploration in valvular disease; leaves open confirmation via prospective trials before practice change.
BACKGROUND: Telemedicine has been associated with better cardiovascular outcomes, but its effects on the regression of mitral regurgitation (MR) and tricuspid regurgitation (TR) remain unknown. OBJECTIVE: This study aimed to evaluate whether telemedicine could facilitate the regression of MR and TR compared to usual care and whether it was associated with better survival. METHODS: This retrospective cohort study enrolled consecutive patients with moderate or greater MR or TR from 2010 through 2020, excluding those with concomitant aortic stenosis, aortic regurgitation, or mitral stenosis greater than mild severity. All patients underwent follow-up transthoracic echocardiography (TTE) at least 3 months apart. Patients receiving telehealth services for at least two weeks within 90 days of baseline TTE were categorized as the telehealth group; the remainder constituted the nontelehealth group. Telemedicine participants transmitted daily biometric data-blood pressure, pulse rate, blood glucose, electrocardiogram, and oxygen saturation-to a cloud-based platform for timely monitoring. Experienced case managers regularly contacted patients and initiated immediate action for concerning measurements. The primary endpoint was MR or TR regression from ≥moderate to <moderate. The secondary endpoint was all-cause death (ACD). The last follow-up ended in December 2022. RESULTS: The MR cohorts consisted of 264 patients (mean age 67 years), including 97 regressors and 74 telehealth participants. Telehealth participation (hazard ratio 2.20, 95% CI 1.35-3.58; P=.001) was robustly associated with MR regression; MR regressors were linked to reverse cardiac remodeling, indicated by improved left ventricular ejection fraction (LVEF), and reduced left ventricular (LV) and left atrial (LA) dimensions (all P≤.005). Determinants of ACD were age (P<.001), LVEF (P<.001), percutaneous coronary intervention (P<.001), and MR regressors (P=.02). The TR cohort consisted of 245 patients (mean age 68 years), including 87 TR regressors and 61 telehealth participants. Telehealth (P=.05) was one of the univariable determinants of TR regression, while beta-blocker use (P=.048) and baseline TR severity (P=.01) remained strong predictors of TR regression in multivariable analysis. CONCLUSIONS: Patients in the telehealth group were 2.2 times more likely to experience MR regression. Moreover, MR regressors had better survival and reverse cardiac remodeling compared to nonregressors. These findings may have important implications for future guidelines.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) conducted a cohort in Mitral or Tricuspid Regurgitation (n=509). Cloud-Based Synchronous Telehealth Program vs. Usual care (nontelehealth group) was evaluated on MR or TR regression from ≥moderate to <moderate (HR 2.20, 95% CI 1.35-3.58, p=.001). A cloud-based synchronous telehealth program was associated with mitral regurgitation regression compared to usual care.
Synapse has enriched 10 related papers. Consider them for comparative context: